声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。近日,兆科眼科宣布,公司核心产品之一、用于治疗湿性(新生血管)老年黄斑部病变(wAMD)的药物TAB014,其生物制剂许可申请(BLA)最近已获中国国家药品监督管理局(“国家药监局”)受理,这是中国首款基于贝伐珠单抗用于治疗wAMD的BLA。TAB014...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.